Market Overview

FDA Says Analysis of Pfizer's Chantix Increased CVE Risk Not Statistical Significant

Share:
Related PFE
Pfizer Announces $3M Grants Program to Further Clinical Research in Advanced Breast Cancer
Hedge Funds' 10 Most Shorted Stocks
Retired Or Soon To Be? Here's A Back Test You Need To Review (Seeking Alpha)

The U.S. FDA is informing the public about the results of a large, combined analysis (called a meta-analysis) of clinical trials that compared patients who received the smoking cessation drug Chantix (varenicline) to patients who received a placebo (an inactive treatment). FDA required the manufacturer of Chantix to conduct the meta-analysis to further evaluate the cardiovascular safety of the drug, and believes it is important to let health care professionals and patients know about the results of this study. FDA first notified the public about a possible increased risk of cardiovascular adverse events with Chantix in its June 2011 Drug Safety Communication (DSC)3.

Posted-In: News FDA

 

Related Articles (PFE)

Around the Web, We're Loving...

Get Benzinga's Newsletters